US International Trade Commission takes on Eli Lilly’s tirzepatide case

The US In­ter­na­tion­al Trade Com­mis­sion is open­ing an in­ves­ti­ga­tion in­to the al­leged sale of un­ap­proved ver­sions of Eli Lil­ly’s weight loss and di­a­betes drug tirzepatide.

The in­ves­ti­ga­tion stems from a com­plaint filed by Lil­ly in Oc­to­ber against sev­er­al on­line phar­ma­cies im­port­ing or sell­ing what Lil­ly claimed are un­ap­proved ver­sions of tirzepatide be­ing “false­ly and mis­lead­ing­ly mar­ket­ed” as Moun­jaro equiv­a­lents. Tirzepatide is mar­ket­ed as Moun­jaro in type 2 di­a­betes and re­cent­ly launched as Zep­bound in obe­si­ty, though off-la­bel use of Moun­jaro for weight loss led to months-long short­ages this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.